市場調查報告書

全球肺動脈高血壓(PAH)市場:成長,趨勢,及預測

Pulmonary Arterial Hypertension Market - Growth, Trends, and Forecast (2020 - 2025)

出版商 Mordor Intelligence LLP 商品編碼 922066
出版日期 內容資訊 英文 111 Pages
商品交期: 2-3個工作天內
價格
全球肺動脈高血壓(PAH)市場:成長,趨勢,及預測 Pulmonary Arterial Hypertension Market - Growth, Trends, and Forecast (2020 - 2025)
出版日期: 2020年01月01日內容資訊: 英文 111 Pages
簡介

本報告提供全球肺動脈高血壓(PAH)市場的相關調查,市場機會和趨勢,成長及阻礙因素,各藥物類別、地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 簡介

  • 調查成果
  • 調查的前提條件
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 市場成長要素
    • 肺動脈高血壓的負擔增加
    • 對孤兒藥(罕見疾病用醫藥品)的開發的政府及民間的支援
  • 市場阻礙因素
    • 藥物分子的專利失效
    • 藥物相關的副作用
  • 波特的五力分析

第5章 市場區隔

  • 各類藥物
    • 前列腺環素、前列腺環素類似體
    • 鈣拮抗劑
    • 磷酸二酯酶5(PDE-5)
    • 內皮素受體拮抗劑(ERA)
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • Arena Pharmaceuticals
    • Bayer AG
    • Bristol-Myers Squibb Company
    • Gilead Sciences, Inc.
    • GlaxoSmithKline Plc
    • Johnson & Johnson (Actelion Pharmaceuticals, Ltd.)
    • Merck & Co. Inc.
    • Novartis International AG
    • Pfizer, Inc.
    • United Therapeutics Corporation

第7章 市場機會及今後趨勢

目錄
Product Code: 67621

Market Overview

Pulmonary arterial hypertension is a group of rare and life-threatening diseases that leads to increased pulmonary arterial pressure and localized hypertension, which can result in heart failure. The increasing prevalence of pulmonary arterial hypertension, government support for the development of orphan drugs and the growing geriatric population are the main factors that are boosting the growth of the pulmonary arterial hypertension market. According to the World Health Organization (WHO), between 2015 and 2050, the proportion of the world's population over 60 years will nearly double from 12% to 22%. The symptoms of Pulmonary arterial hypertension include shortness of breath (dyspnea) especially during exercise, chest pain, and fainting. The increase in the number of geriatrics leads to consequences which is several cases that includes complications related to pulmonary arterial hypertension. The technological advancements are also steadily focusing upon the identification of new molecular pathways which contributes to the development of better treatments possible over the forecast period. All these factors boost the growth of the market.

However, patent expiration of drug molecule and side effects associated with the drugs is expected to impede the growth of the global market in the forecast period.

Scope of the Report

As per the scope of the report, Pulmonary arterial hypertension usually refers to the high blood pressure in the lungs. Treatment of pulmonary arterial hypertension can be done by using drugs such as prostacyclin and prostacyclin analogs, calcium channel blockers, phosphodiesterase 5, endothelin receptor antagonists and others.

Key Market Trends

Prostacyclin and Prostacyclin Analogs Segment is Expected to Observe Better Growth Over the Forecast Period

Based on drug class, the market is segmented into Prostacyclin and Prostacyclin Analogs, Calcium Channel Blockers, Phosphodiesterase 5 (PDE-5), Endothelin Receptor Antagonists (ERA) and Others. Prostacyclin and Prostacyclin Analogs segment is expected to show better growth in the forecast period, owing to the high sales of these drugs. According to the National Organization for Rare Disorders, new cases are estimated to occur in one to two individuals per million each year in the U.S. The incidence is estimated to be similar in Europe. Pulmonary hypertension occurs at all ages, and the incidence of it increases with age. The high growth is attributed to a changing lifestyle, in terms of lack of physical activity and increased consumption of alcohol and tobacco, which increases the chances of developing hypertension and high blood pressure. The increased blood pressure, in turn, gives rise to various diseases such as stroke and heart attacks. Hypertension is considered a variable health risk and is often related to high morbidity and mortality.

North America is Estimated to Lead the Pulmonary Arterial Hypertension Market

North America leads the Pulmonary Arterial Hypertension (PAH) Market, owing to the presence of the highly developed healthcare sector, along with the rising prevalence of infectious and chronic diseases. About 200,000 hospitalizations occur annually in the United States with pulmonary hypertension. Moreover, increased awareness, high diagnosis rate, and supportive government initiatives such as the Rare Disease Act 2002 and The Orphan Drug Act (ODA) 1983 will support market growth. There are certain useful developments shown by the companies and supported by the government related to pulmonary arterial hypertension activities. In 2019, Bayer announced recipients of the inaugural Pulmonary Hypertension Accelerated Bayer (PHAB) Awards, a U.S.-based research grant program created to support clinical research in pulmonary, which is expected to drive the pulmonary arterial hypertension market in the forecast period.

Competitive Landscape

The leading players in the global market for Pulmonary Arterial Hypertension are - Arena Pharmaceuticals, Bayer AG, Bristol-Myers Squibb Company, Gilead Sciences, Inc., GlaxoSmithKline Plc, Johnson & Johnson (Actelion Pharmaceuticals, Ltd.), Merck & Co. Inc., Novartis International AG, Pfizer, Inc., and United Therapeutics Corporation.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Burden of Pulmonary Arterial Hypertension
    • 4.2.2 Government and Private Support for the Development of Orphan Drugs
  • 4.3 Market Restraints
    • 4.3.1 Patent Expiration of Drug Molecule
    • 4.3.2 Side Effects Associated with the Drugs
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Drug Class
    • 5.1.1 Prostacyclin and Prostacyclin Analogs
    • 5.1.2 Calcium Channel Blockers
    • 5.1.3 Phosphodiesterase 5 (PDE-5)
    • 5.1.4 Endothelin Receptor Antagonists (ERA)
    • 5.1.5 Others
  • 5.2 Geography
    • 5.2.1 North America
      • 5.2.1.1 United States
      • 5.2.1.2 Canada
      • 5.2.1.3 Mexico
    • 5.2.2 Europe
      • 5.2.2.1 Germany
      • 5.2.2.2 United Kingdom
      • 5.2.2.3 France
      • 5.2.2.4 Italy
      • 5.2.2.5 Spain
      • 5.2.2.6 Rest of Europe
    • 5.2.3 Asia Pacific
      • 5.2.3.1 China
      • 5.2.3.2 Japan
      • 5.2.3.3 India
      • 5.2.3.4 Australia
      • 5.2.3.5 South Korea
      • 5.2.3.6 Rest of Asia-Pacific
    • 5.2.4 Middle East and Africa
      • 5.2.4.1 GCC
      • 5.2.4.2 South Africa
      • 5.2.4.3 Rest of Middle East and Africa
    • 5.2.5 South America
      • 5.2.5.1 Brazil
      • 5.2.5.2 Argentina
      • 5.2.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Arena Pharmaceuticals
    • 6.1.2 Bayer AG
    • 6.1.3 Bristol-Myers Squibb Company
    • 6.1.4 Gilead Sciences, Inc.
    • 6.1.5 GlaxoSmithKline Plc
    • 6.1.6 Johnson & Johnson (Actelion Pharmaceuticals, Ltd.)
    • 6.1.7 Merck & Co. Inc.
    • 6.1.8 Novartis International AG
    • 6.1.9 Pfizer, Inc.
    • 6.1.10 United Therapeutics Corporation

7 MARKET OPPORTUNITIES AND FUTURE TRENDS